Business Wire

GCORE

6.6.2024 10:31:30 CEST | Business Wire | Press release

Share
Gcore Unveils Inference at the Edge – Bringing AI Applications Closer to End Users for Seamless Real-Time Performance

Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the launch of Gcore Inference at the Edge, a breakthrough solution that provides ultra-low latency experiences for AI applications. This innovative solution enables the distributed deployment of pre-trained machine learning (ML) models to edge inference nodes, ensuring seamless, real-time inference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606719181/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gcore Inference at the Edge empowers businesses across diverse industries with cost-effective, scalable, and secure AI model deployment (Graphic: Gcore)

Gcore Inference at the Edge empowers businesses across diverse industries—including automotive, manufacturing, retail, and technology—with cost-effective, scalable, and secure AI model deployment. Use cases such as generative AI, object recognition, real-time behavioural analysis, virtual assistants, and production monitoring can now be rapidly realised on a global scale.

Gcore Inference at the Edge runs on Gcore's extensive global network of 180+ edge nodes, all interconnected by Gcore's sophisticated low-latency smart routing technology. Each high-performance node sits at the edge of the Gcore network, strategically placing servers close to end users. Inference at the Edge runs on NVIDIA L40S GPUs, the market-leading chip designed specifically for AI inference. When a user sends a request, an edge node determines the route to the nearest available inference region with the lowest latency, achieving a typical response time of under 30 ms.

The new solution supports a wide range of fundamental ML and custom models. Available open-source foundation models in the Gcore ML Model Hub include LLaMA Pro 8B, Mistral 7B, and Stable-Diffusion XL. Models can be selected and trained agnostically to suit any use case, before distributing them globally to Gcore Inference at the Edge nodes. This addresses a significant challenge faced by development teams where AI models are typically run on the same servers they were trained on, resulting in poor performance.

Benefits of Gcore Inference at the Edge include:

  • Cost-effective deployment: A flexible pricing structure ensures customers only pay for the resources they use.
  • Inbuilt DDoS protection: ML endpoints are automatically protected from DDoS attacks through Gcore’s infrastructure.
  • Outstanding data privacy and security: The solution features built-in compliance with GDPR, PCI DSS, and ISO/IEC 27001 standards.
  • Model autoscaling: Autoscaling is available to handle load spikes, so a model is always ready to support peak demand and unexpected surges.
  • Unlimited object storage: Scalable S3-compatible cloud storage that grows with evolving model needs.

Andre Reitenbach, CEO at Gcore comments: “Gcore Inference at the Edge empowers customers to focus on getting their machine learning models trained, rather than worrying about the costs, skills, and infrastructure required to deploy AI applications globally. At Gcore, we believe the edge is where the best performance and end-user experiences are achieved, and that is why we are continuously innovating to ensure every customer receives unparalleled scale and performance. Gcore Inference at the Edge delivers all the power with none of the headache, providing a modern, effective, and efficient AI inference experience.”

Learn more at https://gcore.com/inference-at-the-edge

About Gcore
Gcore is the global edge AI, cloud, network, and security solutions provider. Gcore provides its solutions to global leaders in numerous industries. The company manages its own global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM, due to the average response time of 30 ms worldwide. Gcore’s network consists of 180+ points of presence around the world in reliable Tier IV and Tier III data centres, with a total capacity exceeding 200 Tbps.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606719181/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye